Balancing Biopharma’s Supply Chain Priorities

Scroll Down

With intense pressure placed upon the biopharmaceutical industry to rapidly develop and produce COVID-19 vaccines, diagnostics and therapeutics, it is imperative that CDMOs adapt to ensure they can deal with the increased demand and existing commitments.

In this roundtable, Bill Vincent, Genezen Founder, provides insight into how COVID-19 has accelerated demand for clinical products and outlines how CDMOs are dealing with this pressure despite constraints on the supply of raw materials as well as manufacturing capacity issues.

Read the full article here.

 

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more